Navigating the Uncertainties of Antithrombotic Therapy After Transcatheter Patent Foramen Ovale Closure: A Comprehensive Review
Catheterization and Cardiovascular Interventions · 2025
DOI: 10.1002/ccd.70049 ↗At a glance
Übersichtsarbeit in Catheterization and Cardiovascular Interventions, 2025. Written by Eirini Beneki and 13 co-authors. Institution: First Cardiology Department, School of Medicine, Hippokration General Hospital, National and Kapodistrian University of Athens, Athens, Greece. Major MEDLINE topics: Foramen Ovale, Patent, Cardiac Catheterization, Fibrinolytic Agents, Embolism, Paradoxical. Cited 3 times so far (Crossref); 77 references. The full text is freely available (open access, CC BY-NC 4.0). Funded by: The authors received no specific funding for this work..
Abstract (original language)
The patent foramen ovale (PFO), present in 25% of the population, can cause paradoxical embolism and stroke. Transcatheter PFO closure is the gold standard for recurrent embolism with significant inter‐atrial shunting, with recent trials confirming its superiority in reducing ischemic stroke recurrence over medical therapy. However, device‐related thrombosis remains a concern, posing risks of systemic embolism and neurological events. Optimal post‐closure antithrombotic management, including the choice and duration of therapy, remains unclear. Recommendations suggest transient dual antiplatelet therapy followed by long‐term single therapy, but robust evidence is lacking, especially regarding device neo‐endothelization timelines. Current studies often lack long‐term follow‐up, leaving gaps in understanding the incidence and prevention of thrombosis. Future research is crucial to provide evidence‐based guidance and refine personalized treatment strategies for better outcomes.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- First Cardiology Department, School of Medicine, Hippokration General Hospital, National and Kapodistrian University of Athens, Athens, Greece.
- Department of Cardiology, Lausanne University Hospital (CHUV), Lausanne, Switzerland.
- Institut Cardiovasculaire Paris Sud (ICPS), Essonne, France.
- Laboratory of Reliability and Quality Control in Laboratory Hematology (HemQcR), Department of Biomedical Sciences, School of Health & Caring Sciences, University of West Attica (UniWA), Egaleo, Greece.
- Cardiac Rehabilitation Unit, Rehabilitation Clinic 'Villa delle Magnolie', Caserta, Italy.
- Second Department of Neurology, "Attikon" University Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.
ORCID profiles: Eirini Beneki, Kyriakos Dimitriadis, Ioannis Skalidis, Georgios Tsivgoulis, Ole de Backer
Funding
- The authors received no specific funding for this work.
Cite
APA
Beneki, E., Dimitriadis, K., Pyrpyris, N., Tzimas, G., Skalidis, I., Meier, D., Antiochos, P., Kostakis, P., Pavlou, E., Perone, F., Tsivgoulis, G., Aggeli, C., de Backer, O., & Tsioufis, K. (2025). Navigating the Uncertainties of Antithrombotic Therapy After Transcatheter Patent Foramen Ovale Closure: A Comprehensive Review. Catheterization and Cardiovascular Interventions. https://doi.org/10.1002/ccd.70049
Vancouver
Beneki E, Dimitriadis K, Pyrpyris N, Tzimas G, Skalidis I, Meier D, et al. Navigating the Uncertainties of Antithrombotic Therapy After Transcatheter Patent Foramen Ovale Closure: A Comprehensive Review. Catheterization and Cardiovascular Interventions. 2025. doi:10.1002/ccd.70049
BibTeX
@article{Beneki2025,
author = {Beneki, Eirini and Dimitriadis, Kyriakos and Pyrpyris, Nikolaos and Tzimas, Georgios and Skalidis, Ioannis and Meier, David and Antiochos, Panagiotis and Kostakis, Panagiotis and Pavlou, Efthymia and Perone, Francesco and Tsivgoulis, Georgios and Aggeli, Constantina and de Backer, Ole and Tsioufis, Konstantinos},
title = {Navigating the Uncertainties of Antithrombotic Therapy After Transcatheter Patent Foramen Ovale Closure: A Comprehensive Review},
journal = {Catheterization and Cardiovascular Interventions},
year = {2025},
doi = {10.1002/ccd.70049}
}
EUVIMED